Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Chenzhou Hao"'
Autor:
Tianxiao Wu, Yu Pang, Jing Guo, Wenbo Yin, Mingyue Zhu, Chenzhou Hao, Kai Wang, Jian Wang, Dongmei Zhao, Maosheng Cheng
Publikováno v:
Molecules, Vol 23, Iss 2, p 417 (2018)
A series of novel 2,4-diaminoquinazoline derivatives were designed, synthesized, and evaluated as p21-activated kinase 4 (PAK4) inhibitors. All compounds showed significant inhibitory activity against PAK4 (half-maximal inhibitory concentration IC50
Externí odkaz:
https://doaj.org/article/3d0076aed0404249919b4424bc10dd13
Publikováno v:
Chinese Chemical Letters. :108455
Autor:
Tianxiao Wu, Qiaohua Qin, Ruicheng Lv, Nian Liu, Wenbo Yin, Chenzhou Hao, Yin Sun, Chu Zhang, Yixiang Sun, Dongmei Zhao, Maosheng Cheng
Publikováno v:
European journal of medicinal chemistry. 238
Herein, we report the discovery process and antitumor activity of the TRK inhibitor CZw-124 (8o), which is a quinazoline derivative. Starting from a PAK4 inhibitor, we used various drug design strategies, including pharmacophore feature supplementati
Publikováno v:
SSRN Electronic Journal.
Autor:
Liyu Zhao, Mengya Wu, Xin Su, Xiaolin Jiang, Chenzhou Hao, Maosheng Cheng, Dongmei Zhao, Shizhen Zhao, Xiangqian Zhang, Peng Wei
Publikováno v:
Bioorganic & Medicinal Chemistry. 26:3242-3253
To further enhance the anti-Aspergillus efficacy of our previously discovered antifungal lead compound 1, a series of benzoheterocycle analogues were designed, synthesized and evaluated for their in vitro antifungal activity. The most promising compo
Autor:
Haitao Li, Wenbo Yin, Maosheng Cheng, Jing Guo, Chenzhou Hao, Dongmei Zhao, Tianxiao Wu, Mingyue Zhu, Jian Wang, Yu Pang, Fan Zhao
Publikováno v:
European Journal of Medicinal Chemistry. 155:197-209
We have previously described the identification of indolin-2-one-5-carboxamides as potent PAK4 inhibitors. This study expands the structure-activity relationships on our original series by presenting several modifications in the lead compounds, 2 and
Autor:
Wen-Yan Li, Xu-Qiong Xiong, Honglei Xie, Lijuan Hao, Dongmei Zhao, Xinran Wang, Wei Li, Chenzhou Hao, Chunchi Liu
Publikováno v:
Expert Opinion on Therapeutic Patents. 28:331-340
Epidemiological studies have identified that high levels of low-density lipoprotein-cholesterol (LDL-C) and low levels of high-density lipoprotein-cholesterol (HDL-C) are two independent causes of cardiovascular disease (CVD). Statins, niacin and fib
Autor:
Maosheng Cheng, Shizhen Zhao, Mengya Wu, Dongmei Zhao, Liyu Zhao, Xin Su, Peng Wei, Chunchi Liu, Xiangqian Zhang, Chenzhou Hao
Publikováno v:
European Journal of Medicinal Chemistry. 137:96-107
To further enhance the anti-Aspergillus efficacy of our previously discovered antifungal lead compounds (1), a series of aromatic heterocyclic derivatives were designed, synthesized and evaluated for in vitro antifungal activity. Many of the target c
Autor:
Mingyue Zhu, Maosheng Cheng, Jian Wang, Zizheng Yan, Wanxu Huang, Chenzhou Hao, Kai Wang, Tianxiao Wu, Dongmei Zhao, Jing Guo
Publikováno v:
Bioorganic & Medicinal Chemistry. 25:3500-3511
Utilizing a pharmacophore hybridization approach, a novel series of substituted indolin-2-one derivatives were designed, synthesized and evaluated for their in vitro biological activities against p21-activated kinase 4. Compounds 11b, 12d and 12g exh
Autor:
Xiaodong Li, Maosheng Cheng, Meng Chen, Jing Guo, Xiaolin Jiang, Chenzhou Hao, Shuai Song, Kai Wang, Feng Li, Zizheng Yan, Dongmei Zhao, Jian Wang, Wanxu Huang
Publikováno v:
European Journal of Medicinal Chemistry. 131:1-13
Upon analysis of the reported crystal structure of PAK4 inhibitor KY04031 (PAK4 IC50 = 0.790 μM) in the active site of PAK4, we investigated the possibility of changing the triazine core of KY04031 to a quinazoline. Using KY04031 as a starting compo